Menu Close

Results from first human clinical trial offer promising early results for new Alzheimer’s treatment

Alzheimer’s disease is the most common cause of dementia, affecting more than 55 million people worldwide. Currently, the two main approaches for treatments to delay or slow its progression target the buildup of amyloid beta peptides—which form plaques in the spaces between nerve cells in the brain—and the buildup of tau protein, resulting in tangles which damage neurons.